Search Results

You are looking at 1 - 10 of 555 items for :

  • "prostate cancer" x
  • Refine by Access: All x
Clear All
Full access

Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?

Peter R. Carroll and Andrew J. Vickers

“Screening for prostate cancer has been a public health disaster,” announced Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City. At the

Full access

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma

Full access

Prostate Cancer, Version 2.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Maria Ho

Prostate cancer has surpassed lung cancer as the most common cancer in men. Experts generally accept that these changes resulted from prostate-specific antigen (PSA) screening that detected many early-stage prostate cancers. An estimated 233,000 new cases

Full access

Prostate Cancer

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh

Prostate Cancer Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus

Full access

Impact of Prostate Cancer Diagnosis on Noncancer Hospitalizations Among Elderly Medicare Beneficiaries With Incident Prostate Cancer

Amit D. Raval, Suresh Madhavan, Malcolm D. Mattes, Mohamad Salkini, and Usha Sambamoorthi

quality of care for non–cancer-related conditions. For example, among elderly men (age ≥66 years) with localized prostate cancer, the quality of care for acute chronic conditions is neglected. 3 Furthermore, among men of all ages with prostate cancer

Full access

Prostate Cancer Early Detection

Mark H. Kawachi, Robert R. Bahnson, Michael Barry, J. Erik Busby, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Michael S. Cookson, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Richard J. Howe, Paul H. Lange, Hans Lilja, Kevin R. Loughlin, James Mohler, Judd Moul, Robert B. Nadler, Stephen G. Patterson, Joseph C. Presti, Antoinette M. Stroup, Robert Wake, and John T. Wei

Prostate Cancer Early Detection Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform

Full access

Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer

Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee, and Joseph E. Ippolito

Role of Multiparametric MRI in Diagnosis Conventional screening for prostate cancer (PCa) consists of digital rectal examination (DRE) and serum prostate-specific antigen (PSA) testing, followed by transrectal ultrasound (TRUS)–guided prostate

Full access

Management of Metastatic Castration-Resistant Prostate Cancer

Presented by: Sandy Srinivas

Advances in the management of metastatic castration-resistant prostate cancer (mCRPC) include more sophisticated and sensitive imaging modalities that improve cancer detection and staging compared with conventional imaging methods. These methods

Full access

Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic

Lydia T. Madsen, Deborah A. Kuban, Seungtaek Choi, John W. Davis, Jeri Kim, Andrew K. Lee, Delora Domain, Larry Levy, Louis L. Pisters, Curtis A. Pettaway, John F. Ward, Christopher Logothetis, and Karen E. Hoffman

An estimated 1 in 6 men in the United States will be diagnosed with prostate cancer in their lifetime. 1 Although progress has been made, much still needs to be done to improve the diagnosis, treatment, survival, and quality of life for this

Full access

Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study

Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Man Ho Hui, Xuejin Liu, Teddy Tai Loy Lee, Kyle Hui, Jeffrey Shi Kai Chan, Abraham Ka Chung Wai, Wing Tak Wong, Tong Liu, Kenrick Ng, Sharen Lee, Edward Christopher Dee, Qingpeng Zhang, and Gary Tse

Background Prostate cancer is the most common cancer diagnosis among male patients, and in 2019 was one of the main causes of death worldwide, with 487,000 deaths. 1 Known risk factors for prostate cancer include family history, ethnicity, and